Abstract
Background and objectives Stem cell therapies, although promising for treating ischemic arterial diseases, suffer from poor engraftment and the inability to noninvasively monitor and track transplanted cells in vivo. Stem cell microencapsulation in conjunction with an imaging contrast agent provides a means to prevent cell immunorejection and enable cell tracking with appropriate imaging modalities. The objective of this study was to design and evaluate a novel MRIand CT-visible, immunoprotectable alginate microcapsule containing an imaging contrast agent, perfluorooctylbromide (PFOB), for mesenchymal stem cell (MSC) delivery.
Highlights
Background and objectivesStem cell therapies, promising for treating ischemic arterial diseases, suffer from poor engraftment and the inability to noninvasively monitor and track transplanted cells in vivo
The viability of rabbit mesenchymal stem cell (MSC) encapsulated with PFOB was 90 ± 3% immediately after encapsulation and remained high (88 ± 5% at 4 weeks post-encapsulation)
As few as 2 and 5 PFOB microcapsules could be detected in phantoms using c-arm CT and 19F MRI, respectively
Summary
Promising for treating ischemic arterial diseases, suffer from poor engraftment and the inability to noninvasively monitor and track transplanted cells in vivo. Stem cell microencapsulation in conjunction with an imaging contrast agent provides a means to prevent cell immunorejection and enable cell tracking with appropriate imaging modalities. The objective of this study was to design and evaluate a novel MRIand CT-visible, immunoprotectable alginate microcapsule containing an imaging contrast agent, perfluorooctylbromide (PFOB), for mesenchymal stem cell (MSC) delivery
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
